935273-86-2 Usage
Description
Benzyl 3,3-difluorocyclobutanecarboxylate is a carboxylic acid ester derivative, characterized by the presence of a benzyl group and a 3,3-difluorocyclobutanecarboxylate moiety. This organic compound is known for its potential applications in the synthesis of pharmaceuticals and other organic compounds.
Uses
Used in Pharmaceutical Industry:
Benzyl 3,3-difluorocyclobutanecarboxylate is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure allows it to serve as a key building block in the development of new medications, particularly those targeting specific biological pathways or receptors.
Used in Organic Synthesis:
In the field of organic synthesis, benzyl 3,3-difluorocyclobutanecarboxylate is employed as a versatile reagent for the preparation of a wide range of organic compounds. Its ability to undergo various chemical reactions makes it a valuable component in the synthesis of complex molecules and advanced materials.
Check Digit Verification of cas no
The CAS Registry Mumber 935273-86-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,5,2,7 and 3 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 935273-86:
(8*9)+(7*3)+(6*5)+(5*2)+(4*7)+(3*3)+(2*8)+(1*6)=192
192 % 10 = 2
So 935273-86-2 is a valid CAS Registry Number.
935273-86-2Relevant articles and documents
JAK INHIBITORS
-
, (2018/05/03)
Disclosed is a series of JAK inhibitors, which specifically relates to a compound shown in formula (I) or pharmaceutically acceptable salts thereof.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
, (2015/02/19)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF
-
, (2015/02/19)
Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.